File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.0.CO;2-J
- Scopus: eid_2-s2.0-0033995209
- PMID: 10694648
- WOS: WOS:000085658000011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence
Title | Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence |
---|---|
Authors | |
Keywords | Hepatocellular carcinoma Inoperable Recurrence Transarterial chemoembolization |
Issue Date | 2000 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873 |
Citation | Journal Of Surgical Oncology, 2000, v. 73 n. 2, p. 109-114 How to Cite? |
Abstract | Background and Objectives: The role of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) has remained controversial, and its efficacy for postresection intrahepatic recurrence has not been fully assessed. A study was performed to evaluate the treatment results and prognostic factors of TACE treatment in these patients. Methods: Clinicopathologic data and treatment results of 384 patients with inoperable HCC and 100 patients with postresection recurrent HCC treated with TACE were collected prospectively and analyzed. Results: TACE was associated with an overall treatment morbidity rate of 23% (112/484) and mortality rate of 4.3% (21/484). A particularly high mortality rate of 20% (9/45) was observed among patients with tumors > 10 cm and pretreatment serum albumin level ≤ 35 g/L. The overall 1-year, 3-year, and 5-year survival rates from the time of first TACE treatment were 49%, 23%, and 17% respectively. Tumor size ≤ 10 cm and serum albumin level > 35 g/L were independent favorable prognostic factors. TACE in patients with postresection recurrent HCC was associated with less morbidity, mortality, and a better survival outcome compared with patients with primary inoperable HCC, but this was largely related to smaller tumor size and better liver function in the former group at the time of TACE treatment. Conclusions: TACE in patients with inoperable HCC was associated with significant morbidity and mortality, and the survival benefit was limited. Better patient selection in terms of tumor size and liver function may improve treatment results. Patients who have a tumor > 10 cm and poor liver function (serum albumin ≤ 35 g/L) may not be suitable candidates for TACE treatment. (C) 2000 Wiley-Liss, Inc. |
Persistent Identifier | http://hdl.handle.net/10722/83971 |
ISSN | 2021 Impact Factor: 2.885 2020 SCImago Journal Rankings: 1.201 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Poon, RTP | en_HK |
dc.contributor.author | Ngan, H | en_HK |
dc.contributor.author | Lo, CM | en_HK |
dc.contributor.author | Liu, CL | en_HK |
dc.contributor.author | Fan, ST | en_HK |
dc.contributor.author | Wong, J | en_HK |
dc.date.accessioned | 2010-09-06T08:47:23Z | - |
dc.date.available | 2010-09-06T08:47:23Z | - |
dc.date.issued | 2000 | en_HK |
dc.identifier.citation | Journal Of Surgical Oncology, 2000, v. 73 n. 2, p. 109-114 | en_HK |
dc.identifier.issn | 0022-4790 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/83971 | - |
dc.description.abstract | Background and Objectives: The role of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) has remained controversial, and its efficacy for postresection intrahepatic recurrence has not been fully assessed. A study was performed to evaluate the treatment results and prognostic factors of TACE treatment in these patients. Methods: Clinicopathologic data and treatment results of 384 patients with inoperable HCC and 100 patients with postresection recurrent HCC treated with TACE were collected prospectively and analyzed. Results: TACE was associated with an overall treatment morbidity rate of 23% (112/484) and mortality rate of 4.3% (21/484). A particularly high mortality rate of 20% (9/45) was observed among patients with tumors > 10 cm and pretreatment serum albumin level ≤ 35 g/L. The overall 1-year, 3-year, and 5-year survival rates from the time of first TACE treatment were 49%, 23%, and 17% respectively. Tumor size ≤ 10 cm and serum albumin level > 35 g/L were independent favorable prognostic factors. TACE in patients with postresection recurrent HCC was associated with less morbidity, mortality, and a better survival outcome compared with patients with primary inoperable HCC, but this was largely related to smaller tumor size and better liver function in the former group at the time of TACE treatment. Conclusions: TACE in patients with inoperable HCC was associated with significant morbidity and mortality, and the survival benefit was limited. Better patient selection in terms of tumor size and liver function may improve treatment results. Patients who have a tumor > 10 cm and poor liver function (serum albumin ≤ 35 g/L) may not be suitable candidates for TACE treatment. (C) 2000 Wiley-Liss, Inc. | en_HK |
dc.language | eng | en_HK |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873 | en_HK |
dc.relation.ispartof | Journal of Surgical Oncology | en_HK |
dc.rights | Journal of Surgical Oncology. Copyright © John Wiley & Sons, Inc. | en_HK |
dc.subject | Hepatocellular carcinoma | en_HK |
dc.subject | Inoperable | en_HK |
dc.subject | Recurrence | en_HK |
dc.subject | Transarterial chemoembolization | en_HK |
dc.title | Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-4790&volume=73&spage=109&epage=114&date=2000&atitle=Transarterial+chemoembolization+for+inoperable+hepatocellular+carcinoma+and+postresection+intrahepatic+recurrence | en_HK |
dc.identifier.email | Poon, RTP: poontp@hku.hk | en_HK |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | en_HK |
dc.identifier.email | Fan, ST: stfan@hku.hk | en_HK |
dc.identifier.email | Wong, J: jwong@hkucc.hku.hk | en_HK |
dc.identifier.authority | Poon, RTP=rp00446 | en_HK |
dc.identifier.authority | Lo, CM=rp00412 | en_HK |
dc.identifier.authority | Fan, ST=rp00355 | en_HK |
dc.identifier.authority | Wong, J=rp00322 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.0.CO;2-J | en_HK |
dc.identifier.pmid | 10694648 | - |
dc.identifier.scopus | eid_2-s2.0-0033995209 | en_HK |
dc.identifier.hkuros | 48249 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0033995209&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 73 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 109 | en_HK |
dc.identifier.epage | 114 | en_HK |
dc.identifier.isi | WOS:000085658000011 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Poon, RTP=7103097223 | en_HK |
dc.identifier.scopusauthorid | Ngan, H=7102173824 | en_HK |
dc.identifier.scopusauthorid | Lo, CM=7401771672 | en_HK |
dc.identifier.scopusauthorid | Liu, CL=7409789712 | en_HK |
dc.identifier.scopusauthorid | Fan, ST=7402678224 | en_HK |
dc.identifier.scopusauthorid | Wong, J=8049324500 | en_HK |
dc.identifier.issnl | 0022-4790 | - |